Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 1 Primary Myelofibrosis 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma, Malignant 1 Melanoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Gliosarcoma 1 Glioblastoma 1 Central Nervous System Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Blast Crisis 1

Interventions

pembrolizumab 74 Nivolumab 53 Ipilimumab 42 Cyclophosphamide 32 Interleukin-2 24 aldesleukin 23 Temozolomide 17 fludarabine 16 Biopsy 11 trametinib 10 fludarabine phosphate 10 dabrafenib 10 spartalizumab 8 Paclitaxel 8 Dacarbazine 8 sargramostim 7 cemiplimab 7 binimetinib 7 Cisplatin 7 Bevacizumab 7 poly ICLC 6 lenvatinib 6 epacadostat 6 Radiotherapy 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 montanide ISA 51 5 encorafenib 5 atezolizumab 5 Vemurafenib 5 Specimen Handling 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Melanoma × vatalanib × Clear all

NCT00615160 2021-10-06

PTK/ZK in Disseminated Malignant Melanoma

University Hospital Schleswig-Holstein

Phase 1/2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡